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Castleman disease (CD) describes a group of hetero-
geneous hematologic disorders with characteristic his-
topathological features. CD can present with unicentric
ormulticentric (MCD) regions of lymph node enlargement.
Some cases of MCD are caused by human herpesvirus-8
(HHV-8), whereas others are HHV-8–negative/idiopathic
(iMCD). Treatment of iMCD is challenging, and outcomes
can be poor because no uniform treatment guidelines
exist, few systematic studies have been conducted, and
no agreed upon response criteria have been described.
The purpose of this paper is to establish consensus,
evidence-based treatment guidelines based on the se-
verity of iMCD to improve outcomes. An international
Working Group of 42 experts from 10 countries was
convened by the Castleman Disease Collaborative Net-
work to establish consensus guidelines for the man-
agement of iMCD based on published literature, review
of treatment effectiveness for 344 cases, and expert opin-
ion. The anti–interleukin-6 monoclonal antibody siltuximab
(or tocilizumab, if siltuximab is not available) with or with-
out corticosteroids is the preferred first-line therapy for
iMCD. In the most severe cases, adjuvant combination
chemotherapy is recommended. Additional agents are
recommended, tailored by disease severity, as second-
and third-line therapies for treatment failures. Response
criteria were formulated to facilitate the evaluation of
treatment failure or success. These guidelines should help
treating physicians to stratify patients based on disease
severity in order to select the best available therapeutic
option. An international registry for patients with CD
(ACCELERATE, #NCT02817997) was established in Oc-
tober 2016 to collect patient outcomes to increase the
evidence base for selection of therapies in the future.
(Blood. 2018;132(20):2115-2124)
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Introduction
Castleman described the first case of Castleman disease (CD)
involving a single lymph node station, which is now referred to as
unicentric CD.1 Characteristic histopathological features observed
in CD lymph nodes include hyaline vascular, plasmacytic, and
mixed variants.2,3 CD was later observed to affect multiple lymph
node stations, which is known as multicentric Castleman disease
(MCD).4 In 1995, human herpesvirus 8 (HHV-8) was found to be the
etiologic agent of a plasmablastic variant of MCD occurring most
commonly in HIV-infected or otherwise immunocompromised
individuals.5-10 In HHV-8–associatedMCD, viral interleukin-6 (IL-6),
a homolog of human IL-6, promotes a proinflammatory state
accounting for clinical symptomatology and laboratory ab-
normalities, such as anemia, hypoalbuminemia, and elevated
C-reactive protein (CRP). In HHV-8–negative MCD, which com-
prises 33% to 58% ofMCD cases, human IL-6 is themost common
pathological driver, but the exact etiology is unknown; this entity is
also referred to as “idiopathic MCD” (iMCD).11-15 We have pro-
posed 4 etiological hypotheses, including autoimmune, auto-
inflammatory, neoplastic, and pathogenic mechanisms, which are
now being actively investigated through the Castleman Disease
Collaborative Network (CDCN).12,16
The presentation of iMCD is quite varied with some patients having
mild constitutional symptoms, whereas others develop a life-
threatening cytokine storm, organ failure, and death. The diverse
clinical presentation calls for a treatment stratagem that takes into
account the severity of the disease. Further complicating treatment
recommendations is the existence of distinct iMCD subtypes. Some
patients experience thrombocytopenia (T), anasarca (A), fever (F),
reticulin fibrosis of the bone marrow (R), and organomegaly (O), but
generally have normal g-globulin levels, which has recently been
referred to as the TAFRO subtype of iMCD.17,18 Other patients have
more classic iMCD with features attributed to IL-6 excess, such as
thrombocytosis and hypergammaglobulinemia, but less extreme
anasarca.18,19 The TAFRO subtype often has more severe clinical
symptomatology and worse outcome.18,20-22 We and others
have reported that TAFRO patients have highly vascular lymph
nodes and exhibit a different cytokine spectrum with elevated
vascular endothelial growth factor (VEGF) levels, but milder
elevation of IL-6.23-25
Four recent studies in HIV-negative HHV-8 status unknown (be-
lieved to be HHV-8–negative) MCD reported 5-year overall survival
rates of 55% to 77%, reminiscent of the outcomes of malignant
disorders, although a large series from tertiary specialty centers
reported 1-year survival exceeding 90%.11,26-30 The poor outcome
of iMCD may be due to several factors. First, there were no di-
agnostic criteria for iMCDprior to 2017, when the CDCNpublished
the first-ever consensus diagnostic criteria for iMCD.23 Second,
iMCD is a complex orphan disease with an incidence of 1000 to
1500 cases in the United States.31 Consequently, few physicians
have substantive experience managing iMCD, and clinical trials are
difficult to conduct. Third, there is a paucity of systematic studies to
guide the treating physician, further compounded by the lack of
uniform response criteria, hampering evaluation of treatment effi-
cacy. Finally, there are no existing recommendations on how to use
available treatment modalities in the context of disease severity.
iMCD has been treated with a wide variety of agents, including
corticosteroids, rituximab, and chemotherapies. More recently,
monoclonal antibodies (mAbs) targeting IL-6 directly (siltuximab)
or the IL-6 receptor (tocilizumab) have been approved for iMCD
therapy.32,33 However, a significant proportion of patients do
not benefit from anti–IL-6 mAbs, and additional therapeutic
options are needed for nonresponders, especially severely afflicted
patients. Herein, we establish comprehensive guidance on the
treatment of iMCD based on review of data from 344 patients,
published literature, and expert opinion provided by a panel of
physicians from the CDCN. Themanagement of HHV-8–associated
MCD and POEMS syndrome–associated MCD is well established
and has been reported elsewhere.34-41
Methods
An international group of 42 participants from the United States,
Japan, China, France, United Kingdom, Germany, Italy, Canada,
Norway, and New Zealand, comprising experts in Hematology/
Oncology, Hematopathology, Infectious Diseases, and Immu-
nology, as well as 2 physician-patients with iMCD, embarked on
the establishment of treatment guidelines for iMCD. TheWorking
Group first met in December 2016 with a follow-up meeting in
December 2017. Three additional Web-based teleconferences
were held in August 2017, November 2017, and March 2018. All
relevant English language publications from 1954 to 2017 were
identified through PubMed and other databases using as MESH
headings Castleman Disease, Multicentric, and TAFRO. All age
groups, including pediatric cases, were included. Clinical trials
conductedwith siltuximab (#NCT00412321, #NCT01024036, and
#NCT01400503) and tocilizumab were also reviewed. Five large
data sets as well as individual case reports (see supplemental
appendix 1, available on the Blood Web site) served as the pri-
mary evidence base.11,21,32,33,39
Based on the panel’s expert opinion, the impact of different
therapeutic interventions was assessed in the context of disease
severity, and recommendations for classification of severity
and response criteria for evaluation of treatment were derived
from the literature. The consensus focused on 3 main topics: (1)
development of iMCD severity criteria, (2) treatment of iMCD,
and (3) development of iMCD response criteria. Categories of
evidence and consensus were modeled after those developed
by the National Comprehensive Cancer Network (https://www.
nccn.org/professionals/physician_gls/categories_of_consensus.
aspx). A modified Delphi process comprising the integration of
evidence provided by the literature and expert opinions was
used to generate the final consensus statement contained in this
paper, which was approved by all authors.
Data sharing statement
All data reviewed for the purposes of generating the consensus
criteria were sourced from publicly available journal articles.
A table describing the aggregate data as well as outcome
calculations is available as a supplemental appendix.
Results
Management of iMCD
To serve as the evidence base for the development of iMCD
management guidelines, a data set of iMCD clinical cases
(n 5 344) and treatment regimens (n 5 479) was assembled
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(summarized in Table 1, complete data set in supplemental
appendix 1).
Evaluation of iMCD severity
If a patient is suspected to have iMCD, a comprehensive set of
testing is recommended to determine if the patient meets the
consensus iMCD diagnostic criteria and assess disease severity
(Table 2).23 Laboratory testing for inflammatory markers and
organ dysfunction is indicated. Computed tomography (CT)
should be performed to visualize the extent of the disease;
CT–positron emission tomography (PET) scanning is a useful
alternative, and high standardized uptake values (.6) should
raise the suspicion of an alternative diagnosis (eg, lymphoma).
The severity of iMCD spans a wide spectrum, with some patients
exhibiting mild symptomatology, whereas others experience
life-threatening organ failure. Based on expert opinion and re-
view of the evidence base, we recommend assessing the severity
of iMCD according to simple criteria (Figure 1) to inform the
appropriate treatment choice as defined in Figure 2. These
criteria are intended to segment patients according to their
performance status and extent of organ dysfunction into 2 broad
categories: nonsevere and severe. Patients with severe iMCD
have evidence of organ dysfunction such as renal failure, ana-
sarca, severe anemia, and pulmonary dysfunction resulting in
poor performance status likely requiring critical care. Laboratory
features include very high CRP levels ($100 g/dL), marked
hypoalbuminemia (#2.0 g/dL), and thrombocytopenia (#100 3
1012/L). Patients with lymphocytic interstitial pneumonitis can
also progress to end-stage pulmonary fibrosis if inadequately
treated.
Nonsevere iMCD
iMCD patients who are not severely sick are typically diagnosed
in the outpatient setting and have a good performance status
without evidence of abnormal organ function, whereas other
patients are more symptomatic and often exhibit an IL-6–driven
inflammatory response that interferes significantly with their
ability to function and work. Clinical symptoms may be intense
enough to require hospitalization, albeit not in intensive care.
We recommend (category 1) using anti–IL-6 mAb therapy with
siltuximab (11 mg/kg every 3 weeks) for all patients with non-
severe iMCD based on the high proportion of responders, the
rigorous nature of the studies underlying the evidence base, and
the low side-effect profile relative to other interventions.
Siltuximab, which has been evaluated in a phase 1 trial (n5 34), a
long-term safety study (n5 19), and a randomized, double-blind
placebo-controlled phase 2 trial (n 5 79), is presently approved
in the United States, Canada, European Union, and Brazil,
among other countries.33,42-47 In the phase 2 study, the only
randomized controlled trial performed in iMCD to date, 79
patients were allocated to siltuximab 11 mg/kg every 3 weeks
or placebo. Durable tumor and symptomatic responses were
achieved in 18 of 53 patients in the siltuximab arm (34%;
1 complete response [CR], 17 partial responses [PRs]) vs 0 of
26 in the placebo arm. Nearly 60% of patients had a durable
Table 1. iMCD clinical case series of 344 patients
Therapy
Patients
(n)
Response/
m* (%)
No response/
m* (%)
Treatment failure/
m* (%)
Data combined from
references
All therapies 344 281/461 (61) 180/461 (39) 163/367 (44) 11,21,32,33,39, supplementary
appendix citations
Corticosteroid monotherapy 117 53/114 (46) 61/114 (54) 62/115 (54) 22,23,44, supplementary
appendix citations
Corticosteroid or cytotoxic
chemotherapy (not
distinguished)
19 12/19 (63) 7/19 (37) NA 21
Cytotoxic chemotherapy (any
time used)
135 102/131 (78) 29/131 (22) 44/105 (42) 7,22,23, supplementary
appendix citations
Anti–IL-6 mAb (without cytotoxic
agent or rituximab)
147 88/144 (61) 56/144 (39) 32/100 (32) 7,22,23,43,44, supplementary
appendix citations
Immunomodulator (without
cytotoxic agent)
27 18/26 (69) 8/26 (31) 10/26 (38) 23, supplementary appendix
citations
Other 16 8/13 (62) 5/13 (38) 12/15 (80) 23, supplementary appendix
citations
No treatment/follow-up only 18 0/14 (0) 14/14 (100) 11/14 (79) 7,22,23, supplementary
appendix citations
Literature review of published case reports, small series, and clinical trials were compiled to inform and substantiate the experience and opinion of the Working Group authors. Cytotoxic
chemotherapy regimens described may include the use of rituximab.
Treatment failure was defined as disease progression while on treatment or insufficient response requiring additional treatments. The main series included in this analysis are referenced.
A detailed breakdown of the data is provided in supplemental appendix 1. The TAFRO case reports are tabulated in Table 3.
m, total number of regimens evaluated (479); m*, number regimens assessed for stated outcome; MDACC, MD Anderson Cancer Center case series; n, number of subjects treated in
each treatment regimen category. Other includes plasma exchange (n5 4), radiation (n5 2), plasma exchange1 corticosteroids (n5 2), IV immunoglobulin (n5 2), Polymyxin B–immobilized
fiber column direct hemoperfusion and cytokine absorption (n 5 1), allogeneic stem cell transplant (n 5 1), Cimetidine (n 5 1), antibiotics (n 5 1), corticosteroids and etanercept (n 5 1),
interferon-a (n 5 1).
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symptomatic response, and 31 patients continued to receive
unblinded siltuximab.33 Although elevated pretreatment IL-6
levels are associated with a trend toward an increased likelihood
of response to siltuximab, IL-6 levels should not be used to guide
treatment decisions. In the phase 2 trial, there were iMCD pa-
tients with low/normal IL-6 levels who responded to siltuximab,
whereas others with high IL-6 levels did not.45
If siltuximab is not available, tocilizumab (8 mg/kg every 2 weeks)
may be used (category 2A). Tocilizumab, which has undergone an
open-label, nonrandomized prospective study of 35 patients and
been reported extensively in the literature, is approved for the
treatment of iMCD in Japan. Like siltuximab, responding patients
showed improvement in constitutional symptoms, normalization
of abnormal laboratory markers such as CRP, hemoglobin, al-
bumin, and immunoglobulin G, and reduction in lymphadenop-
athy with few significant adverse events.32,48,49 The most common
side effects of both siltuximab and tocilizumab are mild throm-
bocytopenia, hypertriglyceridemia, hypercholesterolemia, and
pruritus. The availability of siltuximab and tocilizumab varies among
countries, and the choice between the 2 drugs is currently more
dependent on indication within that country and access, as no
head-to-head trials have been performed to compare efficacy.
If needed, first-line therapy with anti–IL-6 mAb should be ac-
companied by corticosteroid therapy for initial disease control.
The existing data on corticosteroid monotherapy do not
support its use due to limited long-term control and frequent
relapses, except in countries where there is no access to mAb
therapy.11,29,50-55 Combining data from published series, we
noted a high treatment failure rate at 54% (Table 1). Never-
theless, corticosteroids can augment iMCD symptom control
along with anti–IL-6 mAbs.32,33 Patients with more indolent
disease can be treated with lower doses of adjunctive corti-
costeroids (eg, prednisone 1 mg/kg, or equivalent for 4-8 weeks
followed by tapering; category 2B), whereas patients who are
more symptomatic may require higher initial doses of corti-
costeroids (eg, methylprednisolone 2 mg/kg or equivalent)
and more gradual tapering.
Careful inspection of the siltuximab and tocilizumab data and
the clinical experience of the expert panel suggest that patients
with a clear inflammatory syndrome as manifested by symp-
tomatology and biochemical abnormalities are most likely to derive
benefit from anti–IL-6 mAb therapy. In the tocilizumab studies,
virtually all patients had increases in CRP, erythrocyte sedimen-
tation rate (ESR), and fibrinogen as well significant anemia and
hypoalbuminemia.32,48,49 Although no formal response criteria
were employed, 86% of patients remained on therapy for at least
5 years.49 In contrast, the symptomatic response rates in patients
treated with siltuximabwere;60%, and the combined stringently
defined end point of durable symptomatic and lymph node
response was 34%. However, the patients in the siltuximab arm
of the randomized trial were less severely affected as reflected by
low scores on the MCD symptom scale as well as modest ele-
vations in CRP and fibrinogen, and a median serum albumin that
was in the normal range.33,45,47 Strict exclusion criteria for organ
dysfunction and patient selection bias in the randomized siltuximab
trial due to a placebo arm likely contributed to the milder
phenotype in these patients. Of note, ad hoc analysis of the
phase 2 data revealed that patients demonstrating more clinical
and laboratory abnormalities included in the minor criteria of the
iMCD diagnostic criteria had a greater response rate than those
who did not.23
Responses in clinical symptomatology occur rapidly with anti–
IL-6 mAb therapy and should be apparent after 3 to 4 doses.32,46
Laboratory indicators, including hemoglobin, CRP, ESR, and
albumin, should mirror clinical improvements and be followed
initially weekly and then biweekly until normalization.33,42,45 Of
Table 2. Recommended workup of iMCD
Purpose Tests
Inflammatory response CBC, renal function, liver function,
CRP, ESR, fibrinogen,
immunoglobulins & free light
chains, albumin, ferritin*
Histopathology Hypervascular/mixed cellularity/
plasmacytic variant
Virologic status HIV serology, HHV-8 qPCR
(peripheral blood), EBER (lymph
node), LANA-1 (lymph node)
Cytokine profile IL-6, VEGF, sIL-2 receptor†
Imaging CT-PET or CT neck, chest,
abdomen, pelvis
Bone marrow evaluation MGUS, myeloma, reticulin fibrosis
Immunology ANA, rheumatoid factor
Organ function ECHO, pulmonary function
Workup should include excisional lymph node biopsy for histopathologic examination to
confirm features consistent with iMCD, establish histopathologic variety, and to rule out
EBV and HHV-8 infection by EBER and LANA-1 staining. Blood work is helpful to exclude
HIV infection, autoimmune disorders, and monoclonal gammopathy of undetermined
significance (MGUS)/myeloma as well as measure inflammatory markers, determine organ
function, and evaluate cytokines levels, including IL-6 and VEGF.
ANA, antinuclear antibody; CBC, complete blood count; EBER, Epstein-Barr virus-encoded
small RNAs; ECHO, echocardiogram; LANA, latency-associated nuclear antigen; qPCR,
quantitative polymerase chain reaction; sIL-2, soluble interleukin-2.
*Ferritin is measured as an acute phase reactant.
†Soluble IL-2 receptor marks T-cell activation. CT and CT-PET scanning help to visualize the
extent of the disease. Bone marrow examination can exclude a concomitant plasma cell
dyscrasia and screen for megakaryocyte hyperplasia and reticulin fibrosis often observed in
TAFRO-iMCD. The diagnostic criteria have recently been published.23 Additional organ
assessment may be needed in severe cases.
• ECOG ≥ 2
• Stage IV renal dysfunction (eGFR <
 30; Creatinine >3.0)
• Anasarca and/or ascites and/or
 pleural/pericardial effusion
 (effects of hypercytokinemia/low
 albumin)
• Pulmonary involvement /interstitial
 pneumonitis w/dyspnea
• Hemoglobin ≤ 8.0g/dL
Severe iMCD
Figure 1. CDCN severity classification for rapid assessment and allocation of
therapy. Patients with severe iMCD must have at least 2 of the 5 criteria listed above.
Patients should be classified as nonsevere iMCD if the above criteria are notmet. ECOG,
Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate.
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note, both siltuximab and tocilizumab give rise to spuriously
elevated IL-6 levels for 18 to 24 months following the last dose.
Therefore, serum IL-6 levels should not be used to assess re-
sponse.14 Resolution of lymphadenopathy can be slow with
anti–IL-6 mAb therapy with a median time to lymph node re-
sponse of 5 months.33,46 This is because anti–IL-6 mAbs merely
abrogate an important growth signal for lymphocytes and
plasma cells, but do not have direct cytotoxic effects. Early re-
sponse to therapy should be judged using the criteria provided
in Figure 3, defining symptomatic and biochemical response
rather than relying on reduction in lymph node size. Patients
should be followed by serial CT scanning every 3 months until
maximum response has occurred, after which the frequency of
imaging can be reduced to 6 and later 12 months.
Clinical experience of the expert working group with siltuximab
and data reported by Nishimoto et al for tocilizumab suggest
that relapses occur on cessation of therapy.49 Indefinite con-
tinuation of anti–IL-6 mAb therapy in responding patients is
therefore recommended. However, dosing intervals were
safely extended to 6 weeks in 40% of iMCD patients in the long-
term safety study of siltuximab, suggesting that dosing may be
spaced out in some patients.44 If used in combination with other
agents, steroids should be discontinued as early as possible to
minimize side effects.
We recommend rituximab (375 mg/m23 4-8 doses) as a first-line
alternative to anti–IL-6 mAb therapy for patients with nonsevere
iMCD who do not have marked cytokine-driven symptomatology
based on amore limited data set, because rituximab has not been
subjected to systematic study in iMCD and data are confined
to case reports or small series (category 2B evidence).56-61 Most
papers report the use of rituximab along with conventional
chemotherapies. Table 1 presents combined data on cytotoxic
chemotherapy, which often includes rituximab as a component.
In a recently published study of iMCD patients, the CR and PR
rates with rituximab or rituximab-based chemotherapy regimens
as first-line therapy were 20% and 48%, respectively. Rituximab-
treated patients had inferior progression-free survival compared
with those managed with siltuximab.21 In 2 further series, ap-
proximately half of the iMCDpatients failed rituximab.11,39 Despite
the lack of rigorous evaluation, the available data and expert
opinion do support a role for rituximab monotherapy in the
treatment of nonsevere iMCD patients for whom it would be
reasonable to give a limited course of therapy rather than in-
definite anti–IL-6 mAb treatment.
Continued
Immunomodulatory
Agent ± Steroids
Seek Expert Advice/
Consider
Immunomodulatory
Agent
Individualized
Further Therapy
Inadequate
Response
PR/CR
PR/CRPR/CR
Inadequate
Response
Rituximab + Steroids
± Immunomodulatory
Agent
Continued Therapy
Tocilizumab ± Steroids
Siltuximab ± Steroids
Continued Therapy
Tocilizumab ± Steroids
Siltuximab ± Steroids
Tocilizumab ± Steroids
Rituximab ± Steroids*
Siltuximab ± Steroids
Tocilizumab + HD Steroids
(1 week, daily assessment)
Siltuximab + HD Steroids
Combination
Chemotherapy†
x1 cycle
Inadequate
Response
Refer to
Center of
Excellence
or Consult
CD Expert
Severe
Management of iMCD
Nonsevere
Category 1 Evidence
Category 2A Evidence
Category 2B Evidence
Figure 2. Treatment algorithm for iMCD. iMCD patients should be stratified for disease severity per Figure 1. For nonsevere iMCD, siltuximab is recommended as frontline
therapy for patients with nonsevere iMCD. Tocilizumab can be used if siltuximab is not available or approved. Steroids are useful adjunctive therapy, and the dose can be tailored
according to the severity of the disease. Patients responding to anti–IL-6mAb therapy should be continued indefinitely. *For patients withmild symptomatology, a limited course
of rituximab is an alternative option. Patients not responding to anti–IL-6 mAb therapy should be considered for rituximab-based therapy 1 steroids 6 immunomodulatory/
immunosuppressive agents. ♠Immunomodulatory/immunosuppressive agents for second- or third-line therapy include thalidomide, cyclosporine A, sirolimus, anakinra, or
bortezomib, but we recommend consulting with an expert at this stage. For severe iMCD, severe disease must be closely monitored, as life-threatening events may occur in this
population. Severely ill patients should be treated with siltuximab and high-dose steroids, but if no clear response occurs within 1 week (or if status worsens at any time), then
combination chemotherapy should be considered.Whenpossible, expert advice should be sought to identify themost appropriate therapy for a given patient. Further therapy is
best individualized. †Examples of chemotherapy include R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), R-VDT-PACE (rituximab, bortezomib,
dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide), or etoposide/ cyclophosphamide/rituximab. Siltuximab is the preferred anti–IL-6 therapy.
However, in countries where siltuximab is not available or approved, tocilizumab can be used instead. Supporting evidence category 1, green boxes; category 2A, yellow boxes;
category 2B, blue boxes. CTC, common toxicity criteria.
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It is important to note that ;50% of iMCD patients will not
achieve a satisfactory response to first-line anti–IL-6 therapy.
Failure to achieve a satisfactory response, defined as PR or CR
(Figure 3), to first-line therapy should prompt reevaluation of the
original diagnosis to rule out an alternative diagnosis, such as
lymphoma. Anti–IL-6 mAb treatment does not need to be con-
tinued if it was not effective in first-line therapy. Second-line
therapy should comprise rituximab to which immunomodulatory/
immunosuppressive agents (Figure 2), and steroids may be
added. Thalidomide has been combined with rituximab and
steroids because it downregulates IL-6 expression and has anti-
angiogenic properties by modulating VEGF. Thalidomide has
induced remissions in iMCD as a single agent and has also been
valuable in combination with rituximab in both HHV-8–associated
MCD and iMCD (Stephen Schey, Guys and St. Thomas’ NHS
Foundation Trust, oral communication, August 2017).62-64
Third-line therapy for patients who fail both anti–IL-6 mAbs and
rituximab is less well defined. Cytotoxic chemotherapies have
a high response rate in our pooled data analysis (78%), but
treatment failure with relapses are common (42%) and toxicities
are significant (Table 1). Therefore, the consensus opinion is
to avoid cytotoxic chemotherapy unless the patient progresses
to severe iMCD. We recommend use of an immunomodulatory/
immunosuppressive agent because these agents have less
toxicity than chemotherapy and have similar efficacy (69% re-
sponse), albeit in fewer case reports.62-64,65-72 These agents
include cyclosporine A, sirolimus, thalidomide, lenalidomide,
bortezomib, the IL-1b receptor antagonist anakinra, retinoic acid
derivatives, and interferon-a.62,63,65-73 Cyclosporine A has been
used most extensively in iMCD-TAFRO cases, particularly to
improve persistent ascites and thrombocytopenia.20,74-77 Ana-
kinra, which blocks the IL-1b receptor and presumably NF-kB
signaling, has been reported as successful treatment of a
siltuximab-refractory iMCD patient.67,68
Severe iMCD: how to treat the critically ill patient
Based on published data, the proportion of patients with severe
iMCD, who have marked organ dysfunction, poor performance
status, and require critical care, is estimated to be 10% to
20%.11,21 These patients should be promptly started on a high-
dose steroid regimen (eg, methylprednisolone 500 mg daily)
together with siltuximab. For pharmacokinetic reasons, an ac-
celerated, weekly dosing schedule of siltuximab may be used
for 1 month. Patients who immediately respond should con-
tinue on siltuximab at every 3-week intervals indefinitely and
slowly taper steroids.
There is consensus in the Working Group that patients with
severe iMCD are at significant risk of mortality, and expert
advice should be sought. Severe iMCD may not respond
immediately to high-dose steroids and anti–IL-6 mAbs, which
can take weeks to achieve steady state concentration. Still
others may never respond to anti–IL-6 mAbs. Therefore, ag-
gressive intervention with multiagent chemotherapy should be
considered as early as necessary (any sign of deterioration or after
1 week of no response to siltuximab, whichever comes first) to
ablate the hyperactivated immune system and stem the cytokine
storm. Chemotherapy regimens, including those for lymphoma:
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone), CVAD (cyclophosphamide, vincristine, doxorubicin,
dexamethasone), or CVP (cyclophosphamide, vincristine, pred-
nisone); myeloma: VDT-ACE-R (bortezomib, dexamethasone,
thalidomide, doxorubicin, cyclophosphamide, etoposide, ritux-
imab); or etoposide/cyclophosphamide–containing regimens as
used for hemophagocytic lymphohistiocytosis have all been
CR
Overall
Response
Biochemical Lymph
Node
Symptoms
Symptom Improvement
Criteria
PR
SD
PD
CRNormal CRP,
Hemoglobin,
Albumin, GFR
Normalization
to baseline
Improvement in
all 4 symptom
categories, but
not to baseline
Improvement in
at least 1 (but
not all)
symptoms
Any symptoms
worse on ≥2
assessments
>50% improvement
in all of CRP,
Hemoglobin,
Albumin, GFR
<50% improvement
(or < 25%
worsening) in all of
CRP, Hemoglobin,
Albumin, GFR
>25% worsening in
any of CRP,
Hemoglobin,
Albumin, GFR
PR
No PR or
CR
Anorexia
Fever
Weight
Fatigue Decrease of ≥1 CTC
grade point relative
to baseline
Decrease of ≥1 CTC
grade point relative
to baseline
Decrease of ≥1°C
relative to baseline
Increase of ≥5%
relative to baseline>25%
increase
Figure 3. CDCN response criteria based on evaluation of biochemical, lymph node, and symptom response. Biochemical, lymph node, and response criteria have been
detailed in the text. For lymph node response, Cheson criteria have been modified to include assessment of skin manifestations.42 An overall CR requires a complete
biochemical, lymph node, and symptomatic response. An overall PR requires nothing less than a PR across all categories, but not meeting criteria for CR. Overall SD requires no
PD in any of the categories and notmeeting the criteria for CRor PR. Anoverall PDoccurswhen any category has a PD. Symptomatic and biochemical response evaluation shouldbe
done on a monthly basis until maximum response has been achieved. Radiological assessment of lymph node response by CT scanning is first recommended at 6 weeks and at
3-monthly intervals thereafter until maximum regression of lymph nodes has occurred. Lymph node response may take several months in patients treated with anti–IL-6 mAbs.
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employed.18,50,54,78 Combination chemotherapy is appropriate in
poor performance status patients, including those requiring
treatment in the intensive care unit, as control of the cytokine
storm can be life-saving and bring about rapid improvement. As
per Table 1, cytotoxic chemotherapy has the highest overall re-
sponse rate (78%), but considerable toxicities and frequent
relapses deter its use outside of the most severe setting when
the risk/benefit analysis is skewed.29,52,79
The subsequent management of severe iMCD patients who fail
to respond to anti–IL-6 mAb or the first cytotoxic chemotherapy
regimen, or those who relapse, is not well defined and is
mostly done on an ad hoc basis taking into account any
previous response, clinical status, comorbidities, and cytokine
profile. Patients who have elevation of IL-6 prior to starting
anti–IL-6 mAb therapy may still benefit from extended ther-
apy with anti–IL-6 mAb, even if they did not respond dur-
ing the acute episode, whereas others may respond to
immunomodulators/immunosuppressants or salvage cytotoxic
therapy more commonly used in plasma cell malignancies (eg,
VTD [bortezomib, thalidomide, dexamethasone]). Autologous
and allogeneic stem cell transplantation has only been re-
ported in a few cases with mixed results and are therapies of
last resort.80-83
Severe iMCD often presents as the TAFRO subtype. Our anal-
ysis of 49 published iMCD-TAFRO cases with treatment data
revealed that corticosteroids, anti–IL-6 mAbs, cytotoxic che-
motherapies, and cyclosporine A are most often used. These
agents demonstrate initial similar efficacy to the other cohorts,
but higher rates of treatment failures and relapses (Table 3).
Based on the available evidence, we recommend following the
same treatment algorithm as for other cases of iMCD that is
dependent on disease severity and initiate therapy with anti–IL-6
mAb therapy with or without corticosteroids. Among TAFRO
cases, cyclosporine A can be useful therapy for anti–IL-6-
refractory cases particularly to improve persistent ascites and
thrombocytopenia.21,74-77 The Japanese TAFRO research group
recommends high-dose steroids, tocilizumab, and cyclosporine
A for patients with TAFRO syndrome.84 A comprehensive analysis
of a treatment-refractory iMCD-TAFRO patient who sustained
multiple relapses after repeated cycles of chemotherapy showed
upregulation of the mTOR pathway, and remission was suc-
cessfully maintained with sirolimus.85 Early data suggest that
the proteomic profiles of classical and TAFRO-iMCD are
different, supporting the notion that there may be diverse
chemokines/cytokines driving the symptomatology across the
iMCD spectrum.24,25
Evaluation of response
As is evident from the review of published literature, criteria for
response to treatment of iMCD have thus far not been agreed
upon. In the tocilizumab study, the primary end point was based
on improvements in specific laboratory tests, but there was no
aggregated response definition.32 The phase 1 siltuximab study
used Cheson criteria for lymph node response modified to as-
sess the skin lesions of iMCD. This trial introduced a clinical
benefit response assessing 6 iMCD-related clinical features.42,86
In the phase 2 registration study of siltuximab, lymphadenopathy
was similarly assessed, but the symptomatic response was evalu-
ated by the investigators using a complex 34 iMCD-related
symptom score.33
The Food and Drug Administration, in its approval of siltuximab,
commentedon the necessity of a composite response assessment
Table 3. iMCD-TAFRO cases
Therapy Patients (n) Response (%) No response (%) Treatment failure (%)
All therapies 49 65/98 (66) 33/98 (34) 52/98 (53)
Corticosteroid monotherapy 25 9/25 (36) 16/25 (64) 18/25 (72)
Cyclophosphamide-based cytotoxic
chemotherapy
14 13/14 (93) 1/14 (7) 4/14 (29)
Rituximab with cytotoxic agent 1 1/1 (100) 0/1 (0) 0/1 (0)
Rituximab without cytotoxic agent 10 9/10 (90) 1/10 (10) 4/10 (40)
Cytotoxic regimen (without cyclophosphamide
or rituximab)
3 2/3 (67) 1/3 (33) 1/3 (33)
Tocilizumab with or without steroids 20 15/20 (75) 5/20 (25) 10/20 (50)
Siltuximab with or without steroids 1 1/1 (100) 0/1 (0) 1/1 (100)
Cyclosporine A (without cytotoxic agent) 8 6/8 (75) 2/8 (25) 2/8 (25)
Immunomodulators: other than cyclosporine A
(without cytotoxic agent)
9 5/9 (56) 4/9 (44) 5/9 (56)
Other 7 4/7 (57) 3/7 (43) 7/7 (100)
These were compiled from published case reports and small series.
n, number of subjects treated in each treatment regimen category, with a total of 98 regimens evaluated. Other includes plasma exchange (n5 3), plasma exchange1 corticosteroids (n5 2),
polymyxin B–immobilized fiber column direct hemoperfusion and cytokine absorption (n5 1), allogeneic stem cell transplant (n5 1). Please refer to supplemental appendix 1 for complete list
of references.
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for iMCD.87 Therefore, our expert panel established a composite
end point for evaluating response taking into account all cardinal
features of the disease: (a) objective biochemical markers of in-
flammatory response and organ function (hemoglobin, CRP,
albumin, estimated glomerular filtration rate); (b) lymph node
size; and (c) clinical symptoms (fatigue, anorexia, fever, weight
change) as assessed by the clinician (Figure 3).
A biochemical CR requires normalization of all values compared
with baseline. In a PR, there is 50% to 99% improvement in all
laboratory values. In patients with SD, there is a ,50% im-
provement in all laboratory values or ,25% worsening in any
laboratory indicators. Progressive disease (PD) indicates a.25%
worsening in any of the laboratory markers. Lymph node re-
sponse is assessed using modified Cheson criteria as previously
published.42,86 Last, 4 important clinical symptoms are assessed
using the National Cancer Institute Common Terminology Cri-
teria of Adverse Events (version 4). A symptomatic CR requires
normalization of all symptoms. PR requires improvement in the
grades of all 4 symptoms, but they do not have to return to
baseline. SD requires not meeting the criteria for PR or PD, which
occurs if any symptoms worsen on $2 assessments 4 weeks
apart. Evaluation of overall response requires integration of the
3 response categories as defined in Figure 3.
Discussion
The published diagnostic criteria of iMCD, together with the
recognition of the TAFRO-iMCD subtype, provide a framework
for recognizing different clinical entities on the CD spectrum.18,23
We present the first formal guidelines for the treatment of iMCD,
depending on symptom severity. Based on the response criteria
used in the literature and our clinical expertise, we propose
composite response criteria addressing all relevant features of
the disease to evaluate treatment in both clinical practice and
future studies. The present guidelines should assist physicians
with selecting therapy and evaluating response, thereby im-
proving patient outcomes. The preferred treatment of non-
severe iMCD is siltuximab, whereas for some patients with
limited symptomatology, a short course of rituximab is an al-
ternative option. Patients with severe iMCD are a challenge and
may require early intervention with combination chemotherapy
to avoid a fatal outcome. Not all patients will benefit from
siltuximab therapy, especially those who have a very mild in-
flammatory syndrome, or on the other end of the spectrum,
severely ill patients who require a rapid response. Last, it has
become clear that iMCD has a pleomorphic cytokine profile and
that the disease is not driven by IL-6 in all.
There are several important limitations to our treatment rec-
ommendations. It is important to highlight that most recom-
mendations were reached by consensus and are not supported
by prospective, randomized data. Because of the rarity of the
disease, there are no clinical studies available comparing
treatment modalities such as chemotherapy, rituximab, and
anti–IL-6 mAbs. Although the evidence base included clinical
trial data and the largest collection of treatment data analyzed to
date, it should be noted that case reports and retrospective case
series with short follow-up durations make up a large portion of
cases, which are subject to publication bias of successful uses of
novel agents. In addition, the various studies used different
criteria for assessing response (CR, PR, “response”) (eg, the
threshold for a CR in a randomized controlled trial is likely dif-
ferent from that in a case report). Therefore, we aggregated all
response categories into 1 global response category, which is
listed in Table 1. We included a broad range of data from
multiple sources to minimize these limitations. Although anti–
IL-6 mAbs are an important contribution to the therapeutic ar-
mamentarium for iMCD, treatment must be continued long
term. The CDCN established an international registry (www.
CDCN.org/ACCELERATE), which collects data pertaining to
treatment and outcome, to increase the evidence base for se-
lection of therapies in the future. Ongoing research will focus on
defining the etiology and pathogenesis of this complex and rare
disease to promote the development of better and more tar-
geted therapies, particularly for patients who do not benefit from
anti–IL-6 mAb administration.
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